Article Archive For Keyword:
Reverse
AUTHOR: Chaitali MohileDATE: JUN 2010
AUTHOR: Kevin HopsonDATE: SEP 2004
AUTHOR: Kevin HopsonDATE: NOV 2004
AUTHOR: Chaitali MohileDATE: JUN 2010
AUTHOR: Chaitali MohileDATE: OCT 2010
AUTHOR: Chaitali MohileDATE: APR 2011
AUTHOR: Chaitali MohileDATE: AUG 2010
AUTHOR: Koos van der MerweDATE: MAR 2014
AUTHOR: Donald W. Pendergast, Jr.DATE: MAR 2013
AUTHOR: Donald W. Pendergast, Jr.DATE: JAN 2013
AUTHOR: Matt BlackmanDATE: OCT 2013
AUTHOR: Koos van der MerweDATE: NOV 2007
AUTHOR: Chaitali MohileDATE: AUG 2013
AUTHOR: Donald W. Pendergast, Jr.DATE: JUL 2009
AUTHOR: Arthur HillDATE: JUN 2005
AUTHOR: David PennDATE: SEP 2000
AUTHOR: Martin J. PringDATE: DEC 1997
AUTHOR: Giorgos E. Siligardos, Ph.D.DATE: AUG 2003
AUTHOR: Giorgos E. Siligardos, Ph.D.DATE: JUN 2003
Reverse Head And Shoulders For AT&T?
ARTICLE SYNOPSIS...Right now, AT&T seems to be bottoming out in what would be the right shoulder of a reverse head and shoulders formation. Because the price isn't very much above the low part of the shoulder, right now would be a good time to buy before it start
AUTHOR: Steven CoffeyDATE: MAY 2004
Reverse Martingales by James William Ferguson
ARTICLE SYNOPSIS...Reverse Martingales by James William Ferguson
Perhaps the most celebrated legend in gambling lore tells of the French noble who, suspecting that he had detected an aberration in a roulette wheel on the Riviera, sent a team into the hall and had them rec
AUTHOR: James William FergusonDATE: MAR 1990
AUTHOR: Alan R. NorthamDATE: JAN 2010
Stop and Reverse: Lumber's Long Slide
ARTICLE SYNOPSIS...After oscillating through a five-month consolidation between 325 and 360, lumber broke through the bottom of its range, losing 38% on its way to a low of 200. In spite of the occassional one-day rally, lumber is still falling.
AUTHOR: David PennDATE: NOV 2000
AUTHOR: David PennDATE: JUL 2003
AUTHOR: John F. EhlersDATE: SEP 2017
AUTHOR: Chaitali MohileDATE: JUN 2011
VRDN And Its Reverse Stock Splits
ARTICLE SYNOPSIS...Viridian Therapeutics, Inc. (VRDN) is a small cap biopharmaceutical company which engages in the development of proprietary RNA targeted therapeutics. Since its Initial Public Offering in June 2014, the company has reduced the number of its shares throug
AUTHOR: Stella Osoba, CMTDATE: AUG 2024
AUTHOR: Kanwaljit Singh MaujDATE: DEC 2005